Abstract 2163P
Background
In France, cancer is the leading cause of death among men and the second leading cause among women. Currently, supportive care provided to cancer patients in community pharmacies are heterogeneous across the country. In order to structure and standardize pharmaceuticalsupportfor all cancer patients in primary care, TotumLab foundation has created the OncoPharma certification.
Methods
The OncoPharma certification is based on a framework that covers the activities of dispensing treatments andsupportingcancer patients, caregivers and relatives, from the time of diagnosis, during and after cancer, by the entire pharmacy team. The framework presents certified characteristics, the way to implement them, as well as documentary ressources and requested internal controls to ensure compliance. The development of the certification framework is the result of a multidisciplinary collaborative effort, bringing together all healthcare professionals involved in cancer patients care. The OncoPharma certification is accessible to all community pharmacies in France.
Results
In the certification framework, patient care is structured around 14 operational characteristics that are proposed and adapted to each individual situation. Since June 2022, the OncoPharma certification framework has been accredited by the French accreditation committee (COFRAC). This document allowed for the publication of the first clinical guideline for the management of cancer patients in community pharmacies by the Francophone Association of Supportive Oncology Care (AFSOS). As of April 2023, two pharmacies have been certified under OncoPharma, and over 40 others are in the process of certification.
Conclusions
This innovative project is the result of collective and multidisciplinary work to improve the quality of life of patients living with cancer. It promotes communication and coordination among healthcare professionals, as well as training and upskilling of pharmacy teams. This project is part of the continuous improvement and value creation in healthcare. Thanks to the Oncopharma certification, the community pharmacist plays a central role in the care of people with cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
TotumLab.
Funding
TotumLab.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2173P - Exploring the complex needs of older patients receiving targeted therapies and immune checkpoint inhibitors for renal and skin cancers at the Royal Marsden Hospital
Presenter: Niamh Cunningham
Session: Poster session 07
2174P - The impact of exposure to antibiotic (ATB) and proton pump inhibitor (PPI) therapy on immune checkpoint inhibitor (ICI) treatment on overall survival (OS): A population-based study
Presenter: Lawson Eng
Session: Poster session 07
2175P - Sex and age-related differences in immunotherapy-induced toxicities
Presenter: Mafalda Teixeira da Costa
Session: Poster session 07
2176P - Rechallenge of immune checkpoint inhibitors after immune-related adverse events: A systematic review
Presenter: Jin Young Kim
Session: Poster session 07
2177P - Immunotherapy adverse events association with inflammation scores: A real-world data analysis from a Portuguese hospital
Presenter: Catarina Fernandes
Session: Poster session 07
2179P - Prospective monitoring of autoimmune events in cancer immunotherapy patients: A report on the first 658 patients in the PRAISE study
Presenter: Eden Sebbag
Session: Poster session 07
2180P - Detrimental effect of an early exposure to antibiotics on the outcomes of immunotherapy in a multi-tumor cohort of patients
Presenter: Víctor Albarrán
Session: Poster session 07
2181P - Effect of different corticosteroid treatment strategies on checkpoint inhibitors pneumonitis outcomes
Presenter: Hui Guo
Session: Poster session 07
2182P - Patient involvement to improve prospective follow-up: Quality of life data after cancer immunotherapy from the PRAISE study
Presenter: Eden Sebbag
Session: Poster session 07
2183P - The relevance of HFpEF in immunotherapy-induced myocarditis: An analysis of 65 patients
Presenter: Adam Chapman
Session: Poster session 07